Compare DDL & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDL | RCEL |
|---|---|---|
| Founded | 2014 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.2M | 403.3M |
| IPO Year | 2021 | 2018 |
| Metric | DDL | RCEL |
|---|---|---|
| Price | $1.74 | $15.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.71 |
| AVG Volume (30 Days) | 293.5K | ★ 562.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.20 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $71,610,000.00 |
| Revenue This Year | $15.28 | $33.70 |
| Revenue Next Year | $9.66 | $23.47 |
| P/E Ratio | $16.08 | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $1.67 | $3.22 |
| 52 Week High | $3.41 | $18.43 |
| Indicator | DDL | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 52.78 |
| Support Level | N/A | $14.67 |
| Resistance Level | $2.00 | $16.90 |
| Average True Range (ATR) | 0.10 | 1.26 |
| MACD | -0.00 | -0.26 |
| Stochastic Oscillator | 11.67 | 24.20 |
Dingdong (Cayman) Ltd are a foremost fresh grocery e-commerce company in mainland China with sustainable growth. It directly provide users and households with fresh groceries, prepared food and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. The Group operates and manages its business as a single segment. The Group generates substantially all of its revenues from customers in the PRC.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.